| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8629873 | Diabetes Research and Clinical Practice | 2018 | 28 Pages |
Abstract
The effects of empagliflozin on multiple CRFs account for some but not all of reduced risks of CVOs in the EMPA-REG OUTCOME trial. More comparable control of established CRFs in type 2 diabetes CVO trials of antidiabetic agents with pleiotrophic effects would facilitate the interpretation of the observed outcomes.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Shihchen Kuo, Wen Ye, Justin Duong, William H. Herman,